Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models
Posted inAllergy & Immunology Dermatology news

Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models

A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a promising evidence-based herbal intervention for recalcitrant skin inflammation.
Topical Botanical Solution Cinainu Shows Sustained Efficacy and Safety in Paediatric Alopecia Areata: Insights from the RAAINBOW Trial
Posted inDermatology news Pediatrics

Topical Botanical Solution Cinainu Shows Sustained Efficacy and Safety in Paediatric Alopecia Areata: Insights from the RAAINBOW Trial

The RAAINBOW phase II/III trial demonstrates that Cinainu, a topical botanical solution, significantly improves hair regrowth and quality of life in paediatric patients with moderate-to-severe alopecia areata, offering a well-tolerated alternative to systemic JAK inhibitors with sustained benefits.
Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program
Posted inClinical Updates Dermatology news

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program

This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients with moderate-to-severe hidradenitis suppurativa.